Dr. Matthew David Vesely, MD, PhD

Dr. Vesely practices at Yale Medicine in New Haven, Connecticut.

Dr. Vesely's NPI, 1689013815, was assigned on June 20, 2013. Dr. Vesely holds Connecticut license 56194.

Dr. Vesely's primary practice is Yale Medicine, at 50 Division St, New Haven, CT 06511 in South Central Ct County. The practice phone is (203) 785-2140.

Dr. Vesely's primary practice is Yale Medicine in New Haven, Connecticut. Dr. Vesely is also affiliated with Yale New Haven Hospital. The medical group on file is Yale Health. Dmand AI also links Dr. Vesely to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vesely practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Vesely's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Vesely is licensed in Connecticut.

CMS data shows 516 Medicare services from Dr. Vesely across 8 procedure codes in 2024, for 205 Medicare patients. Medicare paid $33,490 for them. Every service was in an office.

CMS counts 205 Medicare patients who saw Dr. Vesely in 2024. The largest group is 65 to 74, with 92 patients. 75% of them have high cholesterol, and 69% have high blood pressure. 20% are also on Medicaid. Their average risk score is 1.32, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Vesely's median patient age at 71, with 51% women.

In 2024, Dr. Vesely wrote 929 Medicare Part D claims for 270 patients. 67% of them were for generic drugs. CMS names the drug for 762 of them, across 20 drugs with 11 or more claims each, at $1,226,001 in total drug cost. In 2023, CMS named 855 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Vesely for performance year 2024, reported as part of a group. Dr. Vesely accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Vesely as offering telehealth. CMS counts 121 procedures of removal of skin lesions by Dr. Vesely, more than 76% of the clinicians it reports for that procedure.

Lower limb (leg) arthroscopy (minimally invasive joint repair): 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 13 papers to Dr. Vesely, published from 2016 to 2025. 2021 was the busiest year, with 2. Dr. Vesely has published most often in JAAD Case Rep. Dr. Vesely's most frequent co-authors are Michael Murphy, MD, Keith A. Choate, MD, PhD and Tariq Ahmad, MD.

Dmand AI links Dr. Vesely to 1 clinical trial. Conditions studied include Granuloma Annulare and Necrobiotic Disorders.

CMS Open Payments shows 19 general payments to Dr. Vesely from 9 drug and device companies from 2017 to 2022. Food and beverage make up the largest share, 46% of the total. Abbvie Inc. paid the most, $1,488.